Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719015 | 0.84 | HTT (0.53) | HTTCA12CA1CA2CA5A | |
| SCHEMBL514864 | 0.82 | HTT (0.51) | HTTCA12CA1CA2CA5A | |
| SCHEMBL28365141 | 0.81 | CA12 (0.55) | HTTCA12CA1CA2CA5A | |
| SCHEMBL27946506 | 0.81 | L3MBTL1 (0.47) | KDM4EPOLBHPGDLMNASMN1; SMN2 | |
| SCHEMBL514863 | 0.81 | HTT (0.50) | HTTCA12CA1CA2CA5A | |
| SCHEMBL30297734 | 0.81 | CA2 (0.58) | HTTCA12CA1CA2CA5A | |
| SCHEMBL1694632 | 0.81 | CA2 (0.58) | HTTCA12CA1CA2CA5A | |
| SCHEMBL14378243 | 0.81 | HTT (0.50) | HTTCA12CA1CA2CA5A | |
| SCHEMBL5984089 | 0.81 | KDM4E (0.54) | HTTCA12CA1CA2CA5A | |
| SCHEMBL7237280 | 0.79 | KDM4E (0.53) | HTTCA12CA1CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309502-A1 | ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATEMENT | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023158815-A1 | ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATMENT | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| CN-114685399-A | Preparation method of urapidil intermediate 1- (2-methoxyphenyl) piperazine and salt thereof | 河北广祥制药有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20230309502-A1 | ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATEMENT | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023158815-A1 | ANIMAL LITTER COMPOSITIONS AND METHOD OF AMMONIA ABATMENT | CONTROLLED RELEASE TECHNOLOGIES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-110407741-B | Anti-inflammatory compound and preparation and application thereof | 启元生物(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114685399-A | Preparation method of urapidil intermediate 1- (2-methoxyphenyl) piperazine and salt thereof | 河北广祥制药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685399-A | Preparation method of urapidil intermediate 1- (2-methoxyphenyl) piperazine and salt thereof | 河北广祥制药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-2231680-B1 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-28 | — | — | EP | disclosed |
| US-7858784-B2 | Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2231680-A2 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | Massachusetts Institute of Technology (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009076622-A2 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-06-18 | — | — | WO | disclosed |
| US-4415574-A | BACTERICIDES; MEDICINES; POTENTIATION OF SULFA DRUGS | S. A. PANMEDICA (FR) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | SOD1, TIMCC, TST | HTT 3512/4885CA12 566/4885CA1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.